TELA Bio Inc (NASDAQ: TELA)’s stock price has plunge by 11.33relation to previous closing price of 1.50. Nevertheless, the company has seen a -10.70% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-06 that MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restricted stock units covering 30,000 shares of its common stock to Jim Hagen, the Company’s Senior Vice President – Strategic Commercial Operations, with a grant date of June 2, 2025 (the “Grant Date”). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of Mr. Hagen’s employment compensation and were granted as an inducement material to his acceptance of employment with TELA Bio.
Is It Worth Investing in TELA Bio Inc (NASDAQ: TELA) Right Now?
Company’s 36-month beta value is 0.79.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TELA is 31.63M, and currently, short sellers hold a 2.07% ratio of that floaft. The average trading volume of TELA on June 20, 2025 was 262.01K shares.
TELA’s Market Performance
TELA stock saw an increase of -10.70% in the past week, with a monthly gain of 45.22% and a quarterly increase of -29.24%. The volatility ratio for the week is 8.95%, and the volatility levels for the last 30 days are 6.52% for TELA Bio Inc (TELA). The simple moving average for the past 20 days is 2.49% for TELA’s stock, with a -25.92% simple moving average for the past 200 days.
Analysts’ Opinion of TELA
Many brokerage firms have already submitted their reports for TELA stocks, with Piper Sandler repeating the rating for TELA by listing it as a “Neutral.” The predicted price for TELA in the upcoming period, according to Piper Sandler is $2 based on the research report published on March 21, 2025 of the current year 2025.
Lake Street, on the other hand, stated in their research note that they expect to see TELA reach a price target of $17. The rating they have provided for TELA stocks is “Buy” according to the report published on May 31st, 2022.
TELA Trading at 33.64% from the 50-Day Moving Average
After a stumble in the market that brought TELA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.96% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TELA starting from Cuca Roberto, who purchase 64,444 shares at the price of $2.25 back on Oct 24 ’24. After this action, Cuca Roberto now owns 155,388 shares of TELA Bio Inc, valued at $144,999 using the latest closing price.
Talmo Paul, the Chief Technology Officer of TELA Bio Inc, purchase 22,222 shares at $2.25 during a trade that took place back on Oct 24 ’24, which means that Talmo Paul is holding 91,082 shares at $50,000 based on the most recent closing price.
Stock Fundamentals for TELA
Current profitability levels for the company are sitting at:
- -0.56 for the present operating margin
- 0.67 for the gross margin
The net margin for TELA Bio Inc stands at -0.61. The total capital return value is set at -0.65. Equity return is now at value -267.29, with -58.28 for asset returns.
Based on TELA Bio Inc (TELA), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at -0.88. The debt to equity ratio resting at 2.31. The interest coverage ratio of the stock is -7.68.
Currently, EBITDA for the company is -31.68 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 0.91. The receivables turnover for the company is 6.75for trailing twelve months and the total asset turnover is 0.92. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.22.
Conclusion
In a nutshell, TELA Bio Inc (TELA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
